AstraZeneca Plc is expecting total revenue, at constant exchange rates, to increase by a low-teen percentage this year, on the back of continued demand for its drugs for cancer, respiratory and metabolic diseases. However the forecast doesn’t incorporate any revenue or profit projections from the roll-out of its Covid-19 vaccine, developed jointly with Oxford University, nor its proposed acquisition of Alexion Pharmaceuticals Inc, a US specialty pharma company.
